Gallant Therapeutics announces study for feline stem cell therapyDecember 18, 2023Gallant Therapeutics, an animal health biotechnology company announced the launch of a study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study.
Education Center - SponsoredRethinking Our Approach to Canine OA: Treating synovial inflammationby • Exubrion TherapeuticsIt’s time to reframe arthritis not just as a painful condition, but as a disease of rampant synovial inflammation. In adopting a proactive treatment strategy that is aimed at modulating the inflammatory process, veterinarians can now provide more effective, long-term care.
UC Davis seeks cats with chronic gingivostomatitis for studySeptember 29, 2016A new clinical trial by the University of California, Davis School of Veterinary Medicine is focusing on stem cells to treat cats with chronic gingivostomatitis.
